BACKGROUND: Alemtuzumab (MabCampath, Campath-1H) is a lymphocyte-depleting monoclonal antibody increasingly used in renal transplantation. This article reports the long-term follow-up data from the first series of patients treated with alemtuzumab for biopsy-proven acute rejection (BPAR). METHODS: Fifteen patients were identified who had received alemtuzumab for BPAR between November 1991 and June 1994. Patient and allograft survival were compared with a control group consisting of 25 patients with BPAR from the same era treated with intravenous methyl prednisolone, and with a contemporaneous UK renal transplant cohort. RESULTS: All rejection episodes responded to treatment with alemtuzumab but there was an excess of early infection-associated death in this group. Long-term transplant survival was similar in both groups as was allograft function (mean creatinine concentration at 10 years was 143 micromol/L in alemtuzumab cohort and 183 micromol/L in control cohort, P=0.06). There was no excess incidence of malignancy or cytomegalovirus infection in this prolonged follow-up period.
BACKGROUND:Alemtuzumab (MabCampath, Campath-1H) is a lymphocyte-depleting monoclonal antibody increasingly used in renal transplantation. This article reports the long-term follow-up data from the first series of patients treated with alemtuzumab for biopsy-proven acute rejection (BPAR). METHODS: Fifteen patients were identified who had received alemtuzumab for BPAR between November 1991 and June 1994. Patient and allograft survival were compared with a control group consisting of 25 patients with BPAR from the same era treated with intravenous methyl prednisolone, and with a contemporaneous UK renal transplant cohort. RESULTS: All rejection episodes responded to treatment with alemtuzumab but there was an excess of early infection-associated death in this group. Long-term transplant survival was similar in both groups as was allograft function (mean creatinine concentration at 10 years was 143 micromol/L in alemtuzumab cohort and 183 micromol/L in control cohort, P=0.06). There was no excess incidence of malignancy or cytomegalovirus infection in this prolonged follow-up period.
Authors: Giuseppe Orlando; Peiman Hematti; Robert J Stratta; George W Burke; Pierpaolo Di Cocco; Pierpaolo Di Cocco; Francesco Pisani; Shay Soker; Kathryn Wood Journal: Ann Surg Date: 2010-12 Impact factor: 12.969
Authors: Ronald F Parsons; Kumar Vivek; Robert R Redfield; Thi-Sau Migone; Michael P Cancro; Ali Naji; Hooman Noorchashm Journal: Expert Rev Clin Immunol Date: 2009-11 Impact factor: 4.473
Authors: Ross S Francis; Gang Feng; Thanyalak Tha-In; Ian S Lyons; Kathryn J Wood; Andrew Bushell Journal: Eur J Immunol Date: 2011-01-17 Impact factor: 5.532
Authors: Anne P Bouvy; Mariska Klepper; Michiel G H Betjes; Willem Weimar; Dennis A Hesselink; Carla C Baan Journal: Transplant Direct Date: 2016-05-25